Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker

BACKGROUND: Tumor mutational burden (TMB) is a significant predictor of immune checkpoint inhibitors (ICIs) efficacy. This study investigated the correlation between deep learning radiomic biomarker and TMB, including its predictive value for ICIs treatment response in patients with advanced non-sma...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: He, Bingxi, Dong, Di, She, Yunlang, Zhou, Caicun, Fang, Mengjie, Zhu, Yongbei, Zhang, Henghui, Huang, Zhipei, Jiang, Tao, Tian, Jie, Chen, Chang
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Immunotherapy Biomarkers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7342823/
https://ncbi.nlm.nih.gov/pubmed/32636239
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000550
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados